Catalyst Wire Dossier Catalyst Wire Dossier
CLINICAL_TRIALS ClinicalTrials.gov record update

A Study Evaluating Escalating Doses of 211^At-Labeled Anti-CD45 MAb BC8-B10 (211^At-BC8-B10) Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Open original source record ↗

Record identity and dates

Source
ClinicalTrials.gov
Source record ID
NCT03128034
Title field or adapter rule
protocolSection.identificationModule.officialTitle
Ingested At
2026-04-25T22:28:47.257552+00:00
Published At
2025-12-19T00:00:00+00:00
Record Updated At
2025-12-19
Timestamp Basis
source retrieval time was not retained by the feed adapter
Date limitation
source retrieval time was not retained by the feed adapter

Fields recorded by this source

protocolSection.conditionsModule.conditions
["Acute Lymphoblastic Leukemia", "Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome", "Acute Myeloid Leukemia", "Chronic Myelomonocytic Leukemia", "Myelodysplastic Syndrome With Excess Blasts", "Recurrent Acute Myeloid Leukemia", "Refractory Acute Lymphoblastic Leukemia", "Recurrent Acute Lymphoblastic Leukemia", "Recurrent Mixed Phenotype Acute Leukemia", "Refractory Acute Myeloid Leukemia", "Refractory Mixed Phenotype Acute Leukemia", "Mixed Phenotype Acute Leukemia"]
protocolSection.statusModule.lastUpdatePostDateStruct.date
"2025-12-19"
protocolSection.identificationModule.nctId
"NCT03128034"
protocolSection.identificationModule.officialTitle
"A Study Evaluating Escalating Doses of 211^At-Labeled Anti-CD45 MAb BC8-B10 (211^At-BC8-B10) Followed by Allogeneic Hematopoietic Cell Transplantation for High-Risk Acute Myeloid Leukemia (AML), Acute Lymphoblastic Leukemia (ALL), or Myelodysplastic Syndrome (MDS)"
protocolSection.statusModule.overallStatus
"RECRUITING"
protocolSection.designModule.phases
["PHASE1", "PHASE2"]
protocolSection.statusModule.resultsFirstPostDateStruct.date
""

Study condition terms

  • Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome (protocolSection.conditionsModule.conditions)
  • Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Chronic Myelomonocytic Leukemia (protocolSection.conditionsModule.conditions)
  • Myelodysplastic Syndrome With Excess Blasts (protocolSection.conditionsModule.conditions)
  • Recurrent Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Acute Lymphoblastic Leukemia (protocolSection.conditionsModule.conditions)
  • Recurrent Mixed Phenotype Acute Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Acute Myeloid Leukemia (protocolSection.conditionsModule.conditions)
  • Refractory Mixed Phenotype Acute Leukemia (protocolSection.conditionsModule.conditions)
  • Mixed Phenotype Acute Leukemia (protocolSection.conditionsModule.conditions)

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.